Pseudomonas aeruginosa is a major cause of hospital-acquired infections, and LecB, a lectin that mediates bacterial attachment, biofilm formation, and virulence, is a key factor in its pathogenicity. Inhibition of LecB has been proposed as a promising therapeutic approach for P. aeruginosa infections, with several potential inhibitors, such as conjugate-antibodies, glycomimetic, and small molecules, being explored. This review summarizes recent research on LecB, including its structural and functional properties, its role in bacterial virulence, and its interactions with host cells. The authors highlight the importance of further understanding LecB's mechanisms of action and regulation, as well as its role in P. aeruginosa infections, in order to develop effective treatments. The review concludes by discussing the potential of LecB inhibitors as a novel therapeutic strategy for combating P. aeruginosa infections.